#FDA issues updated information on Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL). Know and consider the risks. https://go.usa.gov/xQxxs   #MedicalDevice

#FDA issues updated information on Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL). Know and consider the risks. https://go.usa.gov/xQxxs  #MedicalDevice
Source: Food and Drug Adminstration (FDA): CDRHNew - Category: Medical Devices Authors: Source Type: news

Related Links:

Authors: Ma M, Zhao R, Yang X, Zhao L, Liu L, Zhang C, Wang X, Shan B Abstract Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma in adults. Mda-7/IL-24 had been identified as a differentiation inducer of B phenotype lymphoma cells. Previous studies have revealed that knockdown of C-myb also leads to the terminal differentiation of B cell lymphoma. The aim of the present study was to investigate the association between the expression of Mda-7/IL-24 and C-myb, and their prognostic significance for DLBCL patients. The tumor tissues were collected from 72 cases of DLBCL patients an...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Authors: Yi X, Zhao Y, Xue L, Zhang J, Qiao Y, Jin Q, Li H Abstract The present study investigated the expression and clinical significance of kelch-like ECH-associated protein 1 (Keap1) and nuclear factor erythroid-2-related factor-2 (Nrf2) expression in diffuse large B-cell lymphoma (DLBCL). These proteins were detected by immunohistochemistry in 39 DLBCL cases and 17 cases of reactive lymph node hyperplasia, and their association with the clinicopathological features of DLBCL patients was analyzed. In DLBCL, the percentage of cells with positive staining for Keap1 and Nrf2 was 46.2 and 35.9%, respectively, which...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
ConclusionsBIA-ALCL is likely to be caused by a complex interplay of factors, allowing for the variation in clinical presentation and disease progression. Our survey has already shown a growing knowledge amongst breast surgeons in the UK and Ireland as well as a switch in practice in less than a third of consultants already.Level of Evidence: not ratable
Source: European Journal of Plastic Surgery - Category: Cosmetic Surgery Source Type: research
Condition:   Follicular Lymphoma Interventions:   Drug: Rituximab;   Drug: Utomilumab;   Drug: Avelumab;   Drug: PF04518600 Sponsors:   Dana-Farber Cancer Institute;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractIt is well established that some rheumatic syndromes (RS) are associated with several hematological malignancies. We aimed to describe the clinical course of patients with hematological malignancies mimicking RS. We studied a series of four patients presenting with apparent RS who were eventually diagnosed with hematological malignancies, and reviewed the relevant literature. Our series consisted of 4 patients, with a mean age of 62.8  ± 20.3 years, who presented to our rheumatology unit between December 2012 and March 2018. Two patients were initially diagnosed with polyarthritis. One of these...
Source: Rheumatology International - Category: Rheumatology Source Type: research
Condition:   Follicular Lymphoma Interventions:   Drug: Rituximab;   Drug: Utomilumab;   Drug: Avelumab;   Drug: PF04518600 Sponsors:   Dana-Farber Cancer Institute;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractBackground.Long‐term childhood cancer survivors (CCS) are at increased risk of adverse cardiovascular events; however, there is a paucity of risk‐stratification tools to identify those at higher‐than‐normal risk.Subjects, Materials, and Methods.This was a population‐based study using data from the Surveillance, Epidemiology, and End Results Program (1973–2013). Long‐term CCS (age at diagnosis ≤19 years, survival ≥5 years) were followed up over a median time period of 12.3 (5–40.9) years. Independent predictors of cardiovascular mortality (CVM) were combined into a risk score, which was...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Symptom Management and Supportive Care, Global Health and Cancer Source Type: research
Veterinary and Comparative Oncology, EarlyView.
Source: Veterinary and Comparative Oncology - Category: Veterinary Research Authors: Source Type: research
Veterinary and Comparative Oncology, EarlyView.
Source: Veterinary and Comparative Oncology - Category: Veterinary Research Authors: Source Type: research
AbstractPurpose of ReviewGenetically engineered T cells expressing a chimeric antigen receptor (CAR-T) targeting specific antigens present on acute lymphoblastic leukemia (ALL) blasts have generated promising results in children and adults with relapsed and refractory disease. We review the current evidence for CAR-T cell therapy in ALL, associated toxicities, and efforts to improve durable response to therapy.Recent FindingsCD19-directed CAR-T cells have recently been approved by the FDA for use in children and young adults with ALL and in adults with diffuse large B cell lymphoma (DLBCL) in the relapsed/refractory settin...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
More News: Lymphoma | Medical Devices | Plastic Surgery